The Effect of Bevacizumab and Ranibizumab Injection

Slides:

Advertisements

Similar presentations

Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M.

Advertisements

Scanning electron microscopic analysis for the quality of diffractive surface of ReSTOR IOL inserted into anterior chamber Department of Ophthalmology.

Physician Compliance With the HEDS Recommendation of Antiviral Prophylaxis in Patients Diagnosed With Herpetic Stromal Keratitis at KEI Sameen Zaidi M.D.

Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Corticosteroids to Treat Bacterial Keratitis Ray KJ, Srinivasan M, Mascarenhas.

Severe Phenotypes of Granular Corneal Dystrophy Type 2 and Genetic Analysis Results Yong Woo Ji, MD, Eung Kweon Kim, MD, PhD, Seung-Il Choi, PhD, Bong-Yoon.

Non-Invasive Keratograph Tear Break-Up Time versus Invasive Fluorescein-Associated Tear Stability Test: Experimental Validation Study Nizar S Abdelfattah,

Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 22, 2005.

Photodynamic Therapy with Verteporfin Combined with Ranibizumab for Corneal Neovascularization Alexandra Peña, MD 1 ; Alejandro Navas, MD, MSc 2 ; Enrique.

Effects of IOP Lowering Agents on Myopic Regression after Refractive Surgery Lim, Taehyung M.D., Hong, So Jin M.D., Cho, Beom Jin M.D., Ph.D. Chung Kyu-Hyung.

Ki Cheol Chang, MD 1, 2, Mee Kum Kim, MD 1, 2, Won Ryang Wee, MD 1,2, Jin Hak Lee, MD 2,3, Beom Seok Jeon, MD 4 Department of Ophthalmology, Seoul National.

Purpose: Introduction:  At initial evaluation: For post-op day # 0 patients: Pre-op VA was 20/50.6 (0.395 ± 0.198); Post-op VA was 20/102.0 (0.196 ± 0.162);

The Differences of Depth Parameters of Deposits Depending on the Morphology in Granular Corneal Dystrophy Type Ⅱ by Fourier Domain Optical Coherence Tomography.

Management of Aniridic Keratopathy with Allograft Limbal Stem Cell Transplantation Followed by Phacoemulsification Surgery Sibel Aksoy, MD, Yonca A. Akova,

Cheil Eye Hospital Young Jeung Park, MD Jong Wook Lee, MD

Subconjunctival Bevacizumab and Fluorometholone to resolve infectious keratitis and decrease corneal neovascularisation: randomized trial Authors Prakashchand.

PRESENCE OF FREE RADICALS IN INTRACAMERAL AGENTS COMMONLY USED DURING CATARACT SURGERY ELISABETH CA MACDONALD, DAVID LOCKINGTON, KANNA RAMAESH Authors.

Phase IIIb Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration PIER Study Year 1 Regillo CD,

CC Teng Effect of Subconjunctival Bevacizumab on Pterygiums Christopher C. Teng, MD 1,2 Lawrence Jacobson, MD 1 1 New York University School of Medicine.

Clinical outcomes of Epi-LASIK : 1-Year-Long Results of Flap ON/OFF with Mitomycin-C ON/OFF Gil-Joong Yoon (MD/PhD) 1 Seong-Taeck Kim (MD) 2 Jae-Woong.

Inhibition of Experimental Corneal Neovascularization by Bevacizumab (Avastin) Baskent University, School of Medicine Department of Ophthalmology, Ankara.

Different epithelial cleavage planes produced by various epikeratomes in Epi-LASIK Doh Lee, M.D., Ph.D. 1, Suk kyue Choi, M.D. 1, Jin Hyoung Kim, M.D.

Michael A. Morris, MD PGY-3 Ophthalmology Resident Scott & White Eye Institute Temple, TX  Authors have no financial interests.

Comparison of Central Corneal Thickness and Peripheral Corneal Thickness using Sheimpflug system, Optical Coherence Tomography and Ultrasound Pachymetry.

EFFECT OF RESVERATROL AND BEVACIZUMAB ON EXPERIMENTAL CORNEAL NEOVASCULARIZATION Selim Doganay, MD¹; Penpe Gul Firat, MD¹; Cem Cankaya, MD¹; Hale Kirimlioglu,

V Dilraj Grewal MD SPS Grewal MD Rajeev Jain, MD G S Brar MD Evaluation of Sub-Conjunctival Bevacizumab as an antiproliferative agent in Glaucoma Filtering.

The Effect of Corneal Anterior Surface Eccentricity on Astigmatism after Cataract Surgery Choul Yong Park MD 1 Sung Jun Lee MD 1 Prabjot Channa MD 2 Roy.

Topical Cyclosporine 0.05% as a Long-Term Monotherapy for Atopic Keratoconjunctivitis Jonathan H. Tzu, M.D ¹, * ; C. Asli Utine, M.D ¹,², * Michael Stern,

Ki-Cheol Chang, MD Department of Ophthalmology, Dankook University Hospital, South Korea Financial disclosure : Author has no commercial associations.

No author has any financial or proprietary interest in any materials or methods mentioned Seung Hyun Kim M.D. ; Tae Hoon Oh M.D. Department of Ophthalmology.

Corneal Tattooing with Amniotic Membrane Woo Chan Park M.D., Won Yeol Ryu M.D. Dept. of Ophthalmology, College of Medicine, Dong-A University Busan, Korea.

Two Cases of Subconjunctival Bevacizumab Injection to Prevent Bleb Failure after Trabeculectomy Dongwook Lee, Min Ahn, In-Cheon You, Daegyu Lee Chonbuk.

Yonca Aydin Akova MD, Leyla Erkanli Asena MD

Hongseok Yang, MD Department of Ophthalmology, Ajou University School of medicine, Suwon, Korea The author has no financial interest.

Effect of pre-op subconjuntival injection of bevacizumab in pterygium surgery Young Jeung Park, M.D. Ph.D. Jong Wook Lee, M.D. Kyoo Won Lee, M.D. Ph.D.

PTERYGIUM AND TOPICAL BEVACIZUMAB: A 2 YEAR FOLLOW UP DR. ADITYA SUDHALKAR,M.S. DR. ANAND SUDHALKAR,M.S. The authors have no financial interest in this.

Simulated Experiments on IOL Power Calculation Using Anterior Segment OCT Dong Hyun Jo, M.D., 1,2 Mee Kum Kim, M.D., 1,2 Won Ryang Wee, M.D. 1,2 1 Department.

COMPARATIVE EFFICACY OF INTRAVITREAL BEVACIZUMAB AND RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR OEDEMA J.A. Montero, J.M. Ruiz-Moreno VISSUM, Alicante.

The results of PTK using Fourier-Domain Optical Coherence Tomography for Granular Corneal Dystrophy Type 2 Eung Kweon Kim, MD, Ph.D 1 ; Tae-im Kim, MD,

CATT objectives To determine whether off-lable “Avastin” works as well as approved medication for neovascular AMD- “Lucentis” To evaluate how often treatment.

The Efficacy and Safety of the Low Intensity Ultrasound Treatment in Patients with Open Angle Glaucoma Hyoung Won Bae, Gong Je Seong, Chan Yun Kim Institute.

Department of Ophthalmology, University of Ulsan College of Medicine,

CRF variations ( initial CRF – final CRF )

Selective laser trabeculoplasty in Korean eyes with medically uncontrolled pseudoexfoliation glaucoma Su Chan Lee1, Jung Hyun Lee1,

Characteristics of Primary Angle-Closure Glaucoma Patients with Normal Intraocular Pressure at the First Visit Won Hyuk Oh1, Bum Gi Kim1, Joo Hwa Lee2.

Outcome of LASIK in Pre-Descemet’s Membrane Corneal Dystrophy

Bevacizumab and corneal patology

FGF-2 DAPI DMEM IL-1 FGF-2 Actin DMEM IL-1 25 KDa 20 KDa

Radwan Almousa, Konstantinos Samaras, Saj Khan, Damian Lake

Lund University Department of Health Sciences, Lund, Faculty of Medicine, Lund University, Sweden Acute abdominal pain; pre hospital evaluation of ketobemidone.

Opacification of the optic of an Akeos Adapt® intraocular lens

Comparison of Central Corneal Thickness measured by

Maayan E. Keshet, M.D. Maggie B. Hymowitz, M.D. John J. Kim, M.D.

The authors have no financial interest

Long-term refractive results after multizone LASIK for extreme myopia

LASIK Application in High Myopic Eyes; 10 Years Survey

Eric Dai MD, Pawan Prasher MD, James McCulley MD, R. Wayne Bowman MD.

Efficacy of Subconjunctival Bevacizumab

Jennifer J. Lee, MD, FAAD, Renee Y. Hsia, MD, MSc

Sun Woong Kim, M.D.1, Hae Jung Sun, M.D.1,

Topical and Subconjunctival Bevacizumab in Corneal Neovascularization in Keratoplasty Patients Vladimir Pfeifer, Petra Schollmayer, Špela Štunf, Alenka.

Cheil Eye Hospital , Daegu, Korea

성모병원 안센터 CHANGES IN ASTIGMATISM RELATIVE TO IOL HAPTIC INSERTION AXIS IN WITH-THE-RULE AND AGAINST-THE-RULE ASTIGMATISM PATIENTS Hyun Seung Kim, M.D.

Bernilla E; Izquierdo Jr. L; Miranda M.

Peter Lee MD, Howard Gimbel MD, Maria Ferensowicz MA

Studený P., Siveková D., Vokrojová M., Farkaš A.

Shorter Duration, Higher Ultraviolet A Irradiation (UVA) Fluence Collagen Cross-linking (CCL) for Keratoconus (KCN) Frank A. Killian, MD and A. John Kanellopoulos,

Authors have no financial interest.

Hyuck Jin Choi, Joo Youn Oh, Won Ryang Wee, Mee Kum Kim,

Young Jeung Park, M.D. Ph.D. Won Suk Choi, M.D.

ASCRS 2010 Joseph A. Donnelly Albert Einstein College of Medicine

Presentation transcript:

The Effect of Bevacizumab and Ranibizumab Injection on Corneal Neovascularization Doh Lee, M.D., Ph.D., Jin Hyoung Kim, M.D., Suk Kyue Choi, M.D., Se Hoon Park, M.D. Department of Ophthalmology, Ilsan Paik Hospital, Inje University College of Medicine, Gyeonggi, Korea Authors have no financial interest

PURPOSE To evaluate the effect of regression and treatment of subconjunctival and intralesional Bevacizumab (AvastinⓇ) and Ranibizumab (LucentisⓇ) injection on corneal neovascularization (CNV) resulting from different ocular surface disorders 연구의 목적은 정상안과 라식후 수술안에서 서로 다른 4가지 각막두께측정계를 통해 중심각막두께를 비교해 보는 것입니다.

METHODS Group I - Bevacizumab - 1.25 mg/0.05cc injection only (n=5) (AvastinⓇ; Genentech, Inc., San Francisco, CA) - 1.25 mg/0.05cc injection only (n=5) under topical anesthesia Group II - Ranibizumab (LucentisⓇ ; Genentech, Inc., San Francisco, CA) - 0.5 mg/0.05cc injection only (n=5)

Corneal herpes infection METHODS Charateristics of patients Causes of NVs Corneal herpes infection Post-KP Lipid degeneration No. of eyes 6 2 Patients were followed up at 1, 7, 30 days after treatment. Used Image J software (Wayne Rasband at the Research Services Branch, National Institute of Mental Health, Bethesda, MD) to analyze the vascularized corneal area.

Results - Area of CNV Bevacizumab 1.25mg/0.05cc injection (Group I) < Post herpetic CNV with corneal opacity > Pre injection Post injection (POD # 7) < Post KP CNV d/t Chemical burn > Pre injection Post injection (POD # 7)

Results - Area of CNV Bevacizumab 1.25mg/0.05cc injection (Group I) < CNV d/t Lipid degeneration > < CNV d/t corneal ulcer > < Post Pterygium OP. > Pre injection Pre injection Pre injection Post injection (POD # 7) Post injection (POD # 7) Post injection (POD # 7)

(By using Image J software) Results - Area of CNV Bevacizumab 1.25mg/0.05cc injection (Group I) (By using Image J software)

Results - Area of CNV Ranibizumab 0.5mg/0.05cc injection (Group II) < Post KP CNV > Pre injection Post injection (POD # 7) < CNV with corneal opacity d/t Lipid keratopathy > Pre injection Post injection (POD # 7)

Results - Area of CNV Ranibizumab 0.5mg/0.05cc injection (Group II) < Post herpetic CNV with corneal opacity > Pre injection Post injection (POD # 7) < Post herpetic CNV with corneal opacity > Pre injection Post injection (POD # 7)

(By using Image J software) Results - Area of CNV Ranibizumab 0.5mg/0.05cc injection (Group II) 중심각막두께의 결과입니다. 중심각막두께의 평균값은 그룹 1~4에서 GALILEI, Pentacam, US ,Orbscan II 순으로 각막두께가 측정되었습니다. (By using Image J software)

Conclusions & Discussions Subconjunctival and intralesional Bevacizumab injection effectively regress CNV induced by various causes, whereas there is no significant effect for CNS after Ranibizumab injection. Bevacizumab injection were seems to be more effective to reduce CNV than Ranibizumab injection. Bevacizumab injection showed significant regression of CNV in short period of time. After one month Bevacizumab injection, CNV had tendency to recur and re-growth.

Conclusions & Discussions Subconjunctival and intralesional Bevacizumab injection could be considered a treatment option for the CNVs. Further research is needed to assess the potential duration, side – effects and minimal effective dose.